Novaferon

Next Previous
Drug Profile

Novaferon

Alternative Names: Recombinant anti-tumour and anti-virus protein - Genova Biotech

Latest Information Update: 27 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genova Biotech Company
  • Developer Genova Biotech Company; The Affiliated Hospital of the Chinese Academy of Military Medical Science
  • Class Antineoplastics; Antivirals; Proteins
  • Mechanism of Action Interferon stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Colorectal cancer
  • Phase II Hepatitis B; Neuroendocrine tumours; Pancreatic cancer

Most Recent Events

  • 17 Oct 2016 Genova suspends a phase-II clinical trial in Pancreatic cancer (Late-stage disease, Second-line therapy or greater) in China prior to October 2016 (Parenteral) (ChiCTR-TRC10001000)
  • 08 Jun 2015 Phase-II development in hepatitis B is ongoing in China.
  • 01 May 2015 The Affiliated Hospital of the Chinese Academy of Military Medical Sciences plans a phase II trial for Neuroendocrine-tumours in China (NCT02455596)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top